Compare TNXP & HQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | HQI |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | 75000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 232.1M |
| IPO Year | 2008 | 2008 |
| Metric | TNXP | HQI |
|---|---|---|
| Price | $9.26 | $19.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $44.50 | $19.00 |
| AVG Volume (30 Days) | ★ 374.3K | 20.4K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.25% |
| EPS Growth | ★ 91.75 | 73.08 |
| EPS | N/A | ★ 0.31 |
| Revenue | $13,107,000.00 | ★ $30,640,000.00 |
| Revenue This Year | $319.65 | $0.54 |
| Revenue Next Year | $101.60 | $5.47 |
| P/E Ratio | ★ N/A | $63.03 |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $9.40 | $7.38 |
| 52 Week High | $24.64 | $20.84 |
| Indicator | TNXP | HQI |
|---|---|---|
| Relative Strength Index (RSI) | 26.70 | 65.63 |
| Support Level | $9.40 | $11.95 |
| Resistance Level | $12.99 | N/A |
| Average True Range (ATR) | 0.50 | 0.91 |
| MACD | -0.18 | 0.22 |
| Stochastic Oscillator | 3.73 | 66.68 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.